VASCOV: Characterization of the microVAScular Dysfunction in Covid-19 ARDS

Sponsor
Assistance Publique - Hôpitaux de Paris (Other)
Overall Status
Recruiting
CT.gov ID
NCT05074758
Collaborator
National Research Agency, France (Other)
40
1
9
4.4

Study Details

Study Description

Brief Summary

The primary endpoint of this research is to establish that the alveolar dead space is significantly higher in patients with COVID-19 ARDS, compared to patients with non-COVID-19 ARDS.

Secondarily, the investigators want to establish the prognostic value of the alveolar-dead space (measured iteratively) in patients with COVID-19 and non-COVID-19 ARDS, to establish the respective influences of the biological parameters of endothelial damage, of the biological parameters of coagulopathy, of the parameters set on the artificial ventilator on the value of the alveolar dead space; in ARDS patients with COVID-19 and non-COVID-19 ARDS, to establish the prognostic value of the laboratory parameters of endothelial damage and coagulopathy in patients with COVID-19 and non-COVID-19 ARDS.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: alveolar dead-space quantification
  • Diagnostic Test: Coagulation activation and impaired fibrinolysis explorations
  • Diagnostic Test: Endothelial activation / endothelial senescence

Detailed Description

Endothelial damage and coagulation activation at the lung microvascular level may play an important role in the physiopathology of the COVID-19 ARDS. The project aims to prospectively investigate both bedside pulmonary physiological markers and biological markers of coagulopathy and endothelial dysfunction in COVID-19 and non-COVID-19 ARDS patients.

Study Design

Study Type:
Observational
Anticipated Enrollment :
40 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Characterization of the microVAScular Dysfunction in COvid-19 ARDS
Actual Study Start Date :
Dec 10, 2021
Anticipated Primary Completion Date :
Sep 10, 2022
Anticipated Study Completion Date :
Sep 10, 2022

Arms and Interventions

Arm Intervention/Treatment
non-COVID-19 ARDS patients

20 patients with acute respiratory distress syndrome (ARDS) unrelated to COVID-19

Diagnostic Test: alveolar dead-space quantification
measurement of alveolar dead-space based on volumetric capnography

Diagnostic Test: Coagulation activation and impaired fibrinolysis explorations
blood sampling: Fibrinolytic components NETs components Elastase-derived fragments of proteins of interest

Diagnostic Test: Endothelial activation / endothelial senescence
circulating endothelial cells, E-selectin, endoglin, LVEF-A, LVEFR-2, Angiopoietin -1 and -2, cKit and SDF-1 Willebrand factor (activity, antigen, multimeric analysis )

COVID-19 ARDS patients

20 patients with acute respiratory distress syndrome (ARDS) linked to COVID-19

Diagnostic Test: alveolar dead-space quantification
measurement of alveolar dead-space based on volumetric capnography

Diagnostic Test: Coagulation activation and impaired fibrinolysis explorations
blood sampling: Fibrinolytic components NETs components Elastase-derived fragments of proteins of interest

Diagnostic Test: Endothelial activation / endothelial senescence
circulating endothelial cells, E-selectin, endoglin, LVEF-A, LVEFR-2, Angiopoietin -1 and -2, cKit and SDF-1 Willebrand factor (activity, antigen, multimeric analysis )

Outcome Measures

Primary Outcome Measures

  1. Prognostic value of alveolar dead space [Up to 28 days]

    Recording the exhaled CO2 curve (side-stream capnography method) and volume curve, as determined by the mechanical ventilator, and computing the signals with the arterial CO2 partial pressure, reflecting the partial pressure of CO2 in the alveoli participating in gas exchanges), determined on arterial blood gas (ABG) sampling.

Secondary Outcome Measures

  1. Prognostic value of the alveolar dead space (measured iteratively) [20 days]

    To establish the link between alveolar dead-space values and Day 20 mortality

  2. Prognostic value of the alveolar dead space (measured iteratively) [28 days]

    To establish the link between alveolar dead-space values and Day 20 mortality and Day-28 invasive ventilator-free days.

  3. Level of circulating endothelial cells [Up to 28 days]

    To describe the biological parameters of endothelial damage and prognostic value

  4. Level of progenitor cells [Up to 28 days]

    To describe the biological parameters of endothelial damage and prognostic value

  5. Level of circulating stem cells [Up to 28 days]

    To describe the biological parameters of endothelial damage and prognostic value

  6. Level of endothelial proteomics [Up to 28 days]

    To describe the biological parameters of endothelial damage and prognostic value

  7. Level of D-dimers [Up to 28 days]

    To describe the biological parameters of endothelial damage and prognostic value

  8. Level of Willebrand Factor [Up to 28 days]

    To describe the biological parameters of endothelial damage and prognostic value

  9. Level of components of the fibrinolytic system [Up to 28 days]

    To describe the biological parameters of endothelial damage and prognostic value

  10. Level of fragments of plasminogen [Up to 28 days]

    To describe the biological parameters of endothelial damage and prognostic value

  11. Level of the components of the NETs (Neutrophil Extracellular Traps) [Up to 28 days]

    To describe the biological parameters of endothelial damage and prognostic value

  12. Survival rate [90 days]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age> 18 years old

  • Invasive mechanical ventilation in place for less than 48 hours

  • Severe or moderate ARDS (defined according to the Berlin classification)

  • Virological confirmation by PCR of SARS-CoV-2 infection (ARDS COVID-19)

  • Lack of virological confirmation by PCR of SARS-CoV-2 infection (ARDS not linked to COVID-19)

  • Patient information

Exclusion Criteria:
  • Massive pulmonary embolism

  • Chronic respiratory failure under long-term oxygen therapy

  • Dying patient

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hôpital européen Georges Pompidou Paris France 75015

Sponsors and Collaborators

  • Assistance Publique - Hôpitaux de Paris
  • National Research Agency, France

Investigators

  • Study Chair: Jean-Luc Diehl, PhD, AP-HP, Hôpital Européen Georges Pompidou, Paris

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT05074758
Other Study ID Numbers:
  • APHP210693
  • 2021-A01339-32
First Posted:
Oct 12, 2021
Last Update Posted:
Jan 19, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Assistance Publique - Hôpitaux de Paris
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 19, 2022